Unit AS 6: Medicine, Drugs and Clinical Trials

Chapter: Actions of Medicines in the Body Relating to Functionality

Welcome to your study notes for AS 6: Medicine, Drugs and Clinical Trials! Have you ever wondered what happens inside your body when you swallow a painkiller or take an antibiotic? How does a tiny pill know where to go, what to fix, and when to leave?

In this chapter, we explore pharmacology—the science of how medicines interact with living systems. Don't worry if medical terms seem intimidating at first. We will break everything down step-by-step into clear, simple ideas.

The Big Picture: Pharmacodynamics vs Pharmacokinetics

To understand medicines, pharmacologists split drug action into two complementary branches:

1. Pharmacodynamics: What the drug does to the body.
2. Pharmacokinetics: What the body does to the drug.

Memory Trick to Avoid Confusion:
• Dynamics = Drug's effect on the body.
• Kinetics = Kinesis (movement) — how the body moves and processes the drug.

Part 1: Pharmacodynamics (What the Drug Does to the Body)

1. Mechanism of Action (MOA)

The Mechanism of Action (MOA) is the specific biochemical interaction through which a drug produces its pharmacological effect. Think of the MOA as the detailed "how-it-works" instruction manual of the drug at a cellular level.

2. Drug Receptors

Most drugs work by targeting receptors. Receptors are specialized proteins located on cell surfaces or within cells. In a healthy body, natural signaling molecules (such as hormones and neurotransmitters) bind to these receptors to instruct the cell to carry out a specific task.

When a drug enters the system, it targets these exact same receptors to change how cells behave.

3. Agonists, Antagonists, and Partial Agonists

Drugs interact with receptors in different ways. We can understand this using the classic lock-and-key analogy:

A. Full Agonists
• Definition: Drugs that bind to and activate a receptor, mimicking the effect of a natural signaling molecule (e.g., a hormone or neurotransmitter).
• Analogy: A master key that fits the lock perfectly, turns smoothly, and opens the door completely to trigger a full response.

B. Antagonists
• Definition: Drugs that bind to a receptor but do not activate it. Instead, they block the binding site, preventing natural molecules or other drugs from acting.
• Analogy: A key that fits inside the lock but cannot turn. It jams the keyhole so no other key can get in.

C. Partial Agonists
• Definition: Drugs that bind to a receptor but only produce a sub-maximal response compared to a full agonist, even at high concentrations.
• Analogy: A key that fits the lock and turns, but only unlocks the door halfway.

Common Pitfall Alert:
Students often incorrectly assume that an antagonist produces the exact "opposite" biological reaction on its own. In reality, an antagonist simply blocks the receptor site and stops the natural biological response from occurring!

Section Key Takeaway: Pharmacodynamics explains how drugs produce biological changes via their Mechanism of Action (MOA). Drugs bind to cellular receptor proteins as agonists (activating the receptor), antagonists (blocking the receptor), or partial agonists (producing a sub-maximal response).

Part 2: Pharmacokinetics (What the Body Does to the Drug: ADME)

Once a drug enters the body, your body immediately begins processing it. This journey is summarized by the four-stage framework known as ADME:

1. A — Absorption

Absorption is the movement of a drug from its site of administration (such as the digestive tract, skin, or muscle) into the bloodstream.

2. D — Distribution

Distribution is the process by which the drug becomes spread throughout the body's tissues and fluids via the circulatory system.

3. M — Metabolism (Biotransformation)

Metabolism is the chemical alteration of the drug within the body. This process primarily takes place in the liver, converting the drug into forms that are easier for the body to eliminate. Drug metabolism occurs in two main phases:

• Phase I Reactions: Involve nonsynthetic modifications, primarily oxidation, reduction, and hydrolysis. These chemical reactions introduce or expose functional groups on the drug molecule.
• Phase II Reactions: Involve conjugation. In this phase, the body attaches a polar molecule to the drug or its Phase I metabolite to make it significantly more water-soluble.

4. E — Excretion

Excretion is the physical removal of the drug or its metabolites from the body. This occurs primarily via the kidneys (in urine) or through bile (into the feces).

Common Pitfall Alert:
Do not confuse metabolism with excretion!
• Metabolism = chemical alteration of the drug (primarily in the liver).
• Excretion = physical removal of the drug from the body (primarily via the kidneys).

Section Key Takeaway: Pharmacokinetics follows the ADME pathway: Absorption into the bloodstream, Distribution to tissues, Metabolism in the liver (Phase I oxidation/reduction/hydrolysis; Phase II conjugation), and Excretion through the kidneys or bile.

Part 3: Key Pharmacological Standards and Thresholds

To use drugs safely and effectively, medical scientists use specific standards and quantitative measures:

1. Bioavailability

Bioavailability is the fraction of the administered dose that reaches the systemic circulation in an unchanged form.
• An intravenous (IV) injection has 100% bioavailability because the drug is placed directly into the bloodstream.
• Oral tablets generally have lower bioavailability because some of the drug is not absorbed or is altered before reaching systemic circulation.

2. Half-life (\(t_{1/2}\))

The half-life (\(t_{1/2}\)) is the time required for the concentration of the drug in the body to reduce by exactly 50%.
• Clinical Rule of Thumb: A drug is generally considered eliminated from the body after 3 to 5 half-lives.

3. Therapeutic Window

The Therapeutic Window is the safe and effective dosage range between the minimum effective concentration (the lowest amount needed to produce a beneficial effect) and the minimum toxic concentration (the lowest amount that causes harmful side effects or toxicity).

• A wide therapeutic window means the drug is relatively safe with a large margin for error.
• A narrow therapeutic window means dosage must be monitored with extreme precision to avoid toxicity.

Part 4: Coursework and Industrial Application for Unit AS 6

Because Unit AS 6 is internally assessed as part of your Double Award portfolio (weighted at 10% of your total A Level), it is vital to connect these scientific concepts to the pharmaceutical industry context.

When compiling your portfolio tasks:
• Always link theoretical concepts (like ADME pathways and receptor targets) to real-world industrial research and manufacturing.
• Highlight connections to Northern Ireland's pharmaceutical sector, focusing on how local industrial partners and laboratories research drug functionality, formulation, and safety testing.

Quick Review Checklist

Before moving on, make sure you can confidently define and explain:
• The difference between Pharmacodynamics (drug on body) and Pharmacokinetics (body on drug).
• Mechanism of Action (MOA) and how receptors function.
• The functional difference between a full agonist, antagonist, and partial agonist.
• All four stages of ADME.
• The difference between Phase I (oxidation, reduction, hydrolysis) and Phase II (conjugation) metabolism in the liver.
• Bioavailability, Half-life (\(t_{1/2}\)), and the Therapeutic Window.